Latest Filings

Issuer Activity

Overview :: Genomic Health, Inc. (OQ:GHDX) [?]
Business Focus: Biotechnology & Medical Research Share on StockTwits
Recent Price for GHDX
USD 26.46 -0.30 (-1.12%)
NSQ Delayed 15 minutes
Apr 24 Close
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
26.91 38.99 N/A 123,367 825.12
1-Day Low 52-Week Low Yield Avg. Volume  
25.58 25.50 0.0% 209,915  
Log in or sign up for a free account to add this stock to your watch list. During beta also get free PDF company reports for US stocks.

Latest 10 SEC filings (by transaction date) for GHDX within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 9:53pm ET April 24th, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Apr 16/14 Apr 14/14 Shak Steven Direct Ownership Employee Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -41  
Apr 16/14 Apr 14/14 Shak Steven Direct Ownership Employee Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -6,959  
Apr 16/14 Apr 14/14 Shak Steven Direct Ownership Common Stock S - Open market or private sale -41 $26.80
Apr 16/14 Apr 14/14 Shak Steven Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 41 $2.88
Apr 16/14 Apr 14/14 Shak Steven Direct Ownership Common Stock S - Open market or private sale -6,959 $26.24
Apr 16/14 Apr 14/14 Shak Steven Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 6,959 $2.88
Apr 10/14 Apr 8/14 Cole G Bradley Direct Ownership Employee Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -3,000  
Apr 10/14 Apr 8/14 Cole G Bradley Direct Ownership Common Stock S - Open market or private sale -3,000 $27.00
Apr 10/14 Apr 8/14 Cole G Bradley Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 3,000 $2.88
Apr 3/14 Apr 1/14 Fuchs Henry J Direct Ownership Common Stock A - Grant, award or other under Rule 16b-3(d) 376 $26.57
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Latest 10 SEC filings (by filing date) for GHDX within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 9:53pm ET April 24th, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Apr 16/14 Apr 14/14 Shak Steven Direct Ownership Employee Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -41  
Apr 16/14 Apr 14/14 Shak Steven Direct Ownership Employee Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -6,959  
Apr 16/14 Apr 14/14 Shak Steven Direct Ownership Common Stock S - Open market or private sale -41 $26.80
Apr 16/14 Apr 14/14 Shak Steven Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 41 $2.88
Apr 16/14 Apr 14/14 Shak Steven Direct Ownership Common Stock S - Open market or private sale -6,959 $26.24
Apr 16/14 Apr 14/14 Shak Steven Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 6,959 $2.88
Apr 10/14 Apr 8/14 Cole G Bradley Direct Ownership Employee Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -3,000  
Apr 10/14 Apr 8/14 Cole G Bradley Direct Ownership Common Stock S - Open market or private sale -3,000 $27.00
Apr 10/14 Apr 8/14 Cole G Bradley Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 3,000 $2.88
Apr 3/14 Apr 1/14 Fuchs Henry J Direct Ownership Common Stock A - Grant, award or other under Rule 16b-3(d) 376 $26.57
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Sign up for a free account or login above to see the past 6 months of filings sorted by insider. During our beta offer, get free access to company PDF reports.
Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Key People
Kimberly J. Popovits
Chairman of the Board, President, Chief Executive Officer
Dean L. Schorno
Chief Financial Officer
G. Bradley Cole
Chief Operating Officer
Steven Shak
Executive Vice President - Research and Development, Chief Medical Officer
   
Company Contact
Address: 301 Penobscot Drive
REDWOOD CITY CA 94063
Tel: 1-650-5692281
Website: www.genomichealth.com
IR: investor.genomichealth.com
Business Overview
Genomic Health, Inc. (Genomic Health) is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. Its Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction (RT-PCR), in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. As of February 2012, Oncotype DX was evaluated in invasive breast cancer in 13 clinical studies involving more than 4,000 breast cancer patients worldwide. Genomic Health offers its Oncotype DX tests as a clinical service. In March 2012, the Company established a wholly owned subsidiary, InVitae Corporation.
Financial Overview
For the fiscal year ended 31 December 2013, Genomic Health, Inc. revenues increased 11% to $261.6M. Net loss totaled $12.8M vs. income of $8.2M. Revenues reflect United States segment increase of 8% to $223.7M, Other Foreign segment increase of 37% to $37.9M. Net loss reflects Other General and administrative increase from $9M (income) to $9M (expense), Other Research and development increase of 57% to $32.1M (expense).
Employees: 684 as of Dec 31, 2013
Reporting Currency: U.S. Dollars
Enterprise value: $729.12M as of Dec 31, 2013
Annual revenue (TTM): $261.60M as of Dec 31, 2013
EBITDA (TTM): -$5.51M as of Dec 31, 2013
Net annual income (TTM): -$12.76M as of Dec 31, 2013
Free cash flow (TTM): -$2.44M as of Dec 31, 2013
Net Debt Last Fiscal Year: N/A
Shares outstanding: 31,183,620 as of Feb 28, 2014
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization
Competitors with Recent Insider Filings
Quintiles Transnational H (N:Q)
Incyte (OQ:INCY)
United Therapeutics (OQ:UTHR)